[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 29 of about 29
1. Patel SG, Meyers P, Huvos AG, Wolden S, Singh B, Shaha AR, Boyle JO, Pfister D, Shah JP, Kraus DH: Improved outcomes in patients with osteogenic sarcoma of the head and neck. Cancer; 2002 Oct 1;95(7):1495-503
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved outcomes in patients with osteogenic sarcoma of the head and neck.
  • BACKGROUND: The current study reviews the authors' recent institutional experience in the treatment of osteosarcoma of the head and neck (OSHN).
  • Surgery was employed in all 44 patients, neoadjuvant chemotherapy was administered in 30 patients (68%), and postoperative radiation therapy was given to 7 patients (16%).
  • Histologic response was "unfavorable" in 22 of 30 patients (73%) who were treated with neoadjuvant chemotherapy.
  • [MeSH-major] Head and Neck Neoplasms / surgery. Osteosarcoma / surgery
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Child. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Recurrence, Local. Radiotherapy, Adjuvant. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 American Cancer Society.DOI 10.1002/cncr.10849
  • (PMID = 12237918.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Cho SI, Park YH, Cho JH, Ryoo BY, Yang SH, Youn SM, Ko JS: Extraskeletal Ewing's sarcoma of the head and neck presenting as blindness. Korean J Intern Med; 2007 Jun;22(2):133-7
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extraskeletal Ewing's sarcoma of the head and neck presenting as blindness.
  • Extraskeletal Ewing's sarcoma is rarely found in the head and neck regions.
  • We report an unusual case of extraskeletal Ewing's Sarcoma of the parapharynx region in a 49-year-old man who presented with blindness.
  • The final diagnosis was extraskeletal Ewing's sarcoma after biopsy of the internal jugular vein thrombosis by histopathological evaluation and immunohistochemical assay.
  • The patient was treated with systemic chemotherapy and showed improved response with durable remission.
  • [MeSH-major] Blindness. Head and Neck Neoplasms / pathology. Sarcoma, Ewing / pathology
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Humans. Male. Middle Aged. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • Genetic Alliance. consumer health - Blindness.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Laryngol Otol. 2000 Jan;114(1):73-5 [10789420.001]
  • [Cites] Spine (Phila Pa 1976). 2000 Aug 1;25(15):1996-9 [10908947.001]
  • [Cites] Eur Urol. 2001 May;39(5):613-7 [11464048.001]
  • [Cites] Stroke. 1996 Feb;27(2):243-6 [8571417.001]
  • [Cites] Cancer. 1975 Jul;36(1):240-51 [1203852.001]
  • [Cites] Am J Surg Pathol. 1994 May;18(5):486-94 [7513503.001]
  • [Cites] Am J Pathol. 1995 Dec;147(6):1799-810 [7495304.001]
  • [Cites] Radiology. 1969 Jun;92(7):1501-9 [5799839.001]
  • (PMID = 17616033.001).
  • [ISSN] 1226-3303
  • [Journal-full-title] The Korean journal of internal medicine
  • [ISO-abbreviation] Korean J. Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide
  • [Other-IDs] NLM/ PMC2687615
  •  go-up   go-down


3. Thariat J, Italiano A, Peyrade F, Birtwisle-Peyrottes I, Gastaud L, Dassonville O, Thyss A: Very Late Local Relapse of Ewing's Sarcoma of the Head and Neck treated with Aggressive Multimodal Therapy. Sarcoma; 2008;2008:854141

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Very Late Local Relapse of Ewing's Sarcoma of the Head and Neck treated with Aggressive Multimodal Therapy.
  • Ewing's sarcoma's relapse rarely occurs more than two years after the initial diagnosis.
  • We report the case of a 26-year-old man with a history of Ewing's sarcoma of the left maxillary sinus at the age of 10 who presented with a very late local relapse, 16 years after the first occurrence of disease.
  • Ultimate control was achieved after multimodal therapy including surgery, high-dose chemotherapy, and radiotherapy.
  • This report indicates that local relapses of Ewing's sarcoma can be treated with curative intent in selected cases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr Hematol Oncol. 1999 Nov-Dec;21(6):486-93 [10598659.001]
  • [Cites] Cancer. 2000 May 1;88(9):2172-80 [10813731.001]
  • [Cites] Ann Surg. 2003 Oct;238(4):563-7; discussion 567-8 [14530727.001]
  • [Cites] Pediatr Blood Cancer. 2004 Jul;43(1):35-9 [15170887.001]
  • [Cites] J Clin Oncol. 1998 Dec;16(12):3736-43 [9850016.001]
  • [Cites] Pediatr Hematol Oncol. 2006 Jan-Feb;23(1):81-6 [16326417.001]
  • [Cites] Eur J Surg Oncol. 2006 Nov;32(9):974-9 [16621429.001]
  • [Cites] Cancer. 2007 Jul 15;110(2):375-84 [17569105.001]
  • [Cites] Cancer. 1987 Dec 1;60(11):2829-40 [3677016.001]
  • [Cites] Rhinology. 2005 Sep;43(3):225-8 [16218518.001]
  • (PMID = 18528525.001).
  • [ISSN] 1357-714X
  • [Journal-full-title] Sarcoma
  • [ISO-abbreviation] Sarcoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2408707
  •  go-up   go-down


Advertisement
4. Kawakami K, Kawakami M, Puri RK: Nitric oxide accelerates interleukin-13 cytotoxin-mediated regression in head and neck cancer animal model. Clin Cancer Res; 2004 Aug 1;10(15):5264-70
Hazardous Substances Data Bank. NITRIC OXIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nitric oxide accelerates interleukin-13 cytotoxin-mediated regression in head and neck cancer animal model.
  • Receptors for interleukin-13 (IL-13R) are overexpressed on several types of solid cancers including gliobastoma, renal cell carcinoma, AIDS Kaposi's sarcoma, and head and neck cancer.
  • Recombinant fusion proteins IL-13 cytotoxin (IL13-PE38QQR or IL13-PE38) have been developed to directly target IL-13R-expressing cancer cells.
  • To address this issue, we assessed the effect of NO inhibiter N(omega)-monomethyl-l-arginine on IL-13 cytotoxin-mediated cytotoxicity and NO2/NO3 production in HN12 head and neck cancer cells.
  • In addition, antitumor effects and NO levels in HN12 and KCCT873 head and neck tumors xenografted s.c. in nude mice when treated with IL-13 cytotoxin were evaluated by tumor measurement, Western blot, and immunohistochemistry analyses.
  • Based on these studies, we concluded that NO accelerates antitumor effect of IL-13 cytotoxin on head and neck tumor cells.
  • Because IL-13 cytotoxin is currently being tested in the clinic for the treatment of patients with recurrent glioblastoma maltiforme, our current findings suggest maintaining macrophage and NO-producing cellular function for optimal therapeutic effect of this targeted agent.
  • [MeSH-major] Cytotoxins / metabolism. Drug Synergism. Head and Neck Neoplasms / drug therapy. Interleukin-13 / biosynthesis. Nitric Oxide / metabolism
  • [MeSH-minor] Animals. Blotting, Western. Cell Line, Tumor. Disease Models, Animal. Enzyme Inhibitors / pharmacology. Exotoxins. Humans. Immunohistochemistry. Immunotoxins / pharmacology. Macrophages / metabolism. Mice. Mice, Nude. Neoplasm Transplantation. Neoplasms / metabolism. Recombinant Fusion Proteins / chemistry. omega-N-Methylarginine / pharmacology

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15297430.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytotoxins; 0 / Enzyme Inhibitors; 0 / Exotoxins; 0 / IL13-PE38QQR; 0 / Immunotoxins; 0 / Interleukin-13; 0 / Recombinant Fusion Proteins; 27JT06E6GR / omega-N-Methylarginine; 31C4KY9ESH / Nitric Oxide
  •  go-up   go-down


5. Shimomura S, Kikuchi Y, Oka S, Ishitoya J: Local treatment of AIDS-associated bulky Kaposi's sarcoma in the head and neck region. Auris Nasus Larynx; 2000 Oct;27(4):335-8
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local treatment of AIDS-associated bulky Kaposi's sarcoma in the head and neck region.
  • Kaposi's sarcoma (KS) is frequently seen in the head and neck regions of HIV-infected patients.
  • We treated the tongue lesion with intralesional chemotherapy.
  • Unless systemic chemotherapy is effective enough to improve a functional disorder, it is thought that local therapy employing excision or intralesional chemotherapy is one of the common therapeutic option of the otolaryngologist, because this treatment avoids severe side effects caused by systemic chemotherapy or radiotherapy.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Oropharyngeal Neoplasms / therapy. Sarcoma, Kaposi / etiology. Sarcoma, Kaposi / therapy. Tongue Neoplasms / therapy
  • [MeSH-minor] Adult. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Agents, Phytogenic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Injections, Intralesional. Male. Tomography, X-Ray Computed. Vinblastine / administration & dosage. Vinblastine / therapeutic use


6. Sethom A, Akkari K, Hachicha A, Bahri W, Miled I, Benzarti S, Kamel Chebbi M: [Ear nose sarcoma. Report of 3 cases]. Tunis Med; 2010 Jun;88(6):440-4
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ear nose sarcoma. Report of 3 cases].
  • [Transliterated title] Les Sarcomes à localisation ORL. (A propos de 3 Observations).
  • BACKGROUND: Head and neck sarcoma are very rare malignant tumors which can occur on any different ENT localization.
  • AIM: The authors report tree different variety of ENT sarcoma diagnosed and treated at the oto-rhino-laryngological department of military hospital of Tunis.
  • We intend to remind of clinical and histological particularities, therapeutic modalities and finally to evaluate the follow-up.
  • METHODS: From 2001 to 2007, three cases of head and neck sarcomas were diagnosed in ENT department of military hospital of Tunis.
  • In each case, diagnosis was validated by the immunohistochemistry.
  • External irradiation or/and chemotherapy was also indicated for all cases.
  • CONCLUSION: ENT sarcomas are aggressive neoplasm.
  • [MeSH-major] Otorhinolaryngologic Neoplasms / diagnosis. Sarcoma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20517859.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


7. Basić-Jukić N, Bubić-Filipi L, Prgomet D, Djanić Hadzibegović A, Bilić M, Kovac L, Kastelan Z, Pasini J, Mokos I, Basić-Koretić M, Kes P: Head and neck malignancies in Croatian renal transplant recipients. Bosn J Basic Med Sci; 2010 Apr;10 Suppl 1:S37-9
MedlinePlus Health Information. consumer health - Kidney Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Head and neck malignancies in Croatian renal transplant recipients.
  • We reviewed a large series of renal transplant recipients to determine the incidence and outcome of patients with malignant changes located at the head and neck.
  • Demographic data, localization and disease outcome were evaluated in patients who developed cancer.
  • Twenty one patients (1.7%) developed 27 head and neck malignancies.
  • The average time from transplantation to development of cancer was 56.8 months.
  • Of cutaneous malignancies, 88.9% were basal cell carcinoma; one patient had Merkell-cell carcinoma and one patient developed squamous cell carcinoma.
  • Noncutaneous malignancies involved the oral cavity (2 cases of Kaposi's sarcoma and one pharyngeal cancer) and the thyroid gland in 3 patients each.
  • Two patients had post-transplant lymphoproliferative disorder occurring at the head and neck.
  • Radical surgery, radiation, and/or chemotherapy were necessary in 33.3% of patients.
  • Immunosuppression was ceased in one patient with Kaposi's sarcoma who returned to dialysis and died 10 years later from heart failure.
  • An increased incidence of cancer occurring in the head and neck was recorded.
  • Sirolimus is safe alternative to calcineurin-based immunosuppression in patients who developed head and neck malignancies.
  • [MeSH-major] Head and Neck Neoplasms / complications. Head and Neck Neoplasms / etiology. Kidney Transplantation / methods. Renal Insufficiency / therapy
  • [MeSH-minor] Brain Neoplasms / complications. Croatia. Follow-Up Studies. Humans. Immunosuppression. Lymphoproliferative Disorders / etiology. Mouth Neoplasms / complications. Skin Neoplasms / complications. Thyroid Neoplasms / complications. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Prilozi. 2009 Dec;30(2):175-84 [20087258.001]
  • [Cites] Nephrol Dial Transplant. 1995;10 Suppl 1:74-80 [7617285.001]
  • [Cites] Int J Cancer. 1996 May 29;66(5):591-3 [8647617.001]
  • [Cites] Arch Dermatol. 1972 Jan;105(1):107-10 [5009611.001]
  • [Cites] Semin Respir Infect. 1993 Sep;8(3):233-9 [8016484.001]
  • [Cites] Transplantation. 1993 Apr;55(4):742-7 [8475546.001]
  • [Cites] Acta Otolaryngol. 2008 Nov;128(11):1255-8 [18607958.001]
  • [Cites] Kidney Int. 2008 Jan;73(1):136 [18084267.001]
  • (PMID = 20433429.001).
  • [ISSN] 1840-4812
  • [Journal-full-title] Bosnian journal of basic medical sciences
  • [ISO-abbreviation] Bosn J Basic Med Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Bosnia and Herzegovina
  •  go-up   go-down


8. Abdel Rahman H, El-Baradie T, El-Baradie M, Bahaa S, Shalan M: Management Head and Neck Ewing's Sarcoma Family of Tumors: Experience of the National Cancer Institute, Cairo University. J Egypt Natl Canc Inst; 2010 Mar;22(1):41-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management Head and Neck Ewing's Sarcoma Family of Tumors: Experience of the National Cancer Institute, Cairo University.
  • BACKGROUND: Ewing's sarcoma accounts for 4-6% of primary malignant bone tumors and it affects the head and neck in only 1-4% of cases.
  • The purpose of this study was to review the NCI experience with Ewing's sarcoma of the head and neck in children.
  • PATIENTS AND METHODS: A retrospective analysis of patient files with head and neck Ewing's sarcoma treated at the National Cancer Institute, Cairo University, Egypt, during the period from 1997 to 2008 was done.
  • Files were reviewed and data for patients, tumor and treatment profile were extracted.
  • RESULTS: Twenty patients out of 280 with Ewing's sarcoma were identified during an 11-year period.
  • The most common tumor site was in the mandible (9/20, 45%) followed by a neck mass (4/20, 20%) and a clavicular mass (3/20, 15%).
  • Most of the patients (19/20, 95%) received chemotherapy.
  • Local therapy was in the form of radical radiotherapy for 8 patients (40%), 2 patients (10%) had surgery alone, while five patients (25%) had surgical resection and postoperative radiotherapy.
  • CONCLUSION: Ewing's sarcoma of the head and neck is a disease of a rare incidence with debate about the optimum local therapy.
  • Small non-metastatic tumors with good response to chemotherapy have abetter outcome.
  • KEY WORDS: Ewing's sarcoma - Head and neck - Management.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21503005.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  •  go-up   go-down


9. Hammami B, Bouayed W, Siala W, Toumi N, Khabir A, Boudawara T, Frikha M, Daoud J, Charfeddine I, Ghorbel A: [Head and neck sarcoma]. Ann Otolaryngol Chir Cervicofac; 2008 Dec;125(6):294-300
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Head and neck sarcoma].
  • [Transliterated title] Les sarcomes de la tête et du cou.
  • INTRODUCTION: Head and neck sarcomas comprise a heterogeneous and biologically diverse set of rare neoplasms.
  • In an effort to clarify the clinical behavior of head and neck sarcomas and evaluate treatment, we present our experience and review the relevant literature.
  • PATIENTS AND METHODS: This is a retrospective analysis of 15 patients with histologically proven head and neck sarcoma treated in the ENT department between 1998 and 2007.
  • Computed tomography and MRI were done in 66.7% and 60% of the patients, respectively, to evaluate tumor extension.
  • Curative treatment in eight cases was based on different combinations of chemotherapy, radiotherapy, and surgery.
  • CONCLUSION: Head and neck sarcomas present diverse rare neoplasms.
  • They make up 5%-20% of all soft tissue sarcomas.
  • All age groups can be affected by this neoplasm, with no predominance in one sex or the other.
  • The most common histologic type is rhabdomyosarcoma, especially in children.
  • Treatment is based essentially on the association of surgery, radiotherapy, and chemotherapy to optimize therapeutic results.
  • [MeSH-major] Head and Neck Neoplasms. Sarcoma
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Combined Modality Therapy. Female. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Prognosis. Remission Induction. Retrospective Studies. Time Factors. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18937933.001).
  • [ISSN] 0003-438X
  • [Journal-full-title] Annales d'oto-laryngologie et de chirurgie cervico faciale : bulletin de la Société d'oto-laryngologie des hôpitaux de Paris
  • [ISO-abbreviation] Ann Otolaryngol Chir Cervicofac
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


10. Lee N, Shin E: Treatment outcomes for patients with synovial sarcoma of the head and neck. Expert Rev Anticancer Ther; 2008 Mar;8(3):371-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment outcomes for patients with synovial sarcoma of the head and neck.
  • Survival in patients with synovial sarcoma of the head and neck: association with tumor location, size, and extension.
  • Head Neck 29, 731-740 (2007).
  • Synovial sarcoma of the head and neck occurs most commonly in males in their third decade of life.
  • Synovial sarcoma of the head is rare, accounting for less than 10% of all head and neck sarcomas.
  • Due to its rarity, there are very few publications on the treatment approach for these tumors.
  • However, it is uniformly accepted that all head and neck synovial sarcomas should undergo complete surgical resection followed by postoperative radiation therapy in those at high risk for locoregional recurrence.
  • In terms of chemotherapy, there are also emerging data on its effectiveness in the treatment of synovial sarcoma of the head and neck.
  • The paper under evaluation reports a single institution's 36-year experience on the treatment of synovial sarcoma of the head and neck.
  • This paper highlights the importance of a multidisciplinary approach in the treatment of this disease.
  • [MeSH-major] Head and Neck Neoplasms / therapy. Sarcoma, Synovial / therapy
  • [MeSH-minor] Adolescent. Adult. Age Factors. Child. Child, Preschool. Cohort Studies. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Retrospective Studies. Sex Factors. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18366285.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


11. Kuehnemund M, Friedrichs N, Bootz F: [Synovial sarcoma of the head and neck]. Laryngorhinootologie; 2008 Jul;87(7):498-502
Genetic Alliance. consumer health - Synovial sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Synovial sarcoma of the head and neck].
  • BACKGROUND: Synovial sarcoma (SS) is a mesenchymal malignancy, which predominantly occurs at the lower extremities of young adults.
  • Only 3 % of the SS show a primary manifestation in the head and neck region.
  • METHODS: A retrospective chart review (years 2002 - 2006) of our Department of Otorhinolaryngology, head and neck surgery, School of Medicine, Bonn, Germany, was performed searching for patients with primary head and neck manifestations of SS.
  • 3 patients underwent radical surgery followed by chemotherapy, 2 in combination with irradiation.
  • 1 patient underwent primary chemotherapy and irradiation.
  • The histological diagnosis was a biphasic SS as well as a monophasic SS in 2 patients respectively.
  • 2 patients were in complete remission at the recent follow-up, 1 patient died 14 months after diagnosis due to a lethal carotidal haemorrhage.
  • CONCLUSIONS: The aggressive character of the SS as well as its high recurrence rate afford a radical therapeutic scheme enclosing surgical, chemotherapeutical and radiological treatment as well as a thorough follow-up.
  • The genetic translocation t(X;18) leads the way to the right diagnosis.
  • The prognosis of head and neck SS must be considered as poor.
  • SS should be taken into consideration in head and neck tumors of unclear nature.
  • [MeSH-major] Otorhinolaryngologic Neoplasms / diagnosis. Sarcoma, Synovial / diagnosis
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor / analysis. Child. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Lymph Nodes / pathology. Lymphatic Metastasis / diagnosis. Lymphatic Metastasis / pathology. Magnetic Resonance Imaging. Male. Mucin-1 / analysis. Neoplasm Staging. Vimentin / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18231962.001).
  • [ISSN] 0935-8943
  • [Journal-full-title] Laryngo- rhino- otologie
  • [ISO-abbreviation] Laryngorhinootologie
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucin-1; 0 / Vimentin
  •  go-up   go-down


12. Velche-Haag B, Dehesdin D, Proust F, Marie JP, Andrieu-Guitrancourt J, Laquerriere A: [Ewing's sarcoma of the head and neck: a case report]. Ann Otolaryngol Chir Cervicofac; 2002 Dec;119(6):363-8
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ewing's sarcoma of the head and neck: a case report].
  • We report a case of Ewing's sarcoma located in the ethmoid sinus.
  • Diagnosis was established at microscopic examination with histoimmunochemistry and molecular biology.
  • Treatment combined chemotherapy and surgical resection with skull base reconstruction and post-operative ratio and chemotherapy.
  • [MeSH-major] Bone Neoplasms / therapy. Ethmoid Sinus / surgery. Sarcoma, Ewing / therapy
  • [MeSH-minor] Adult. Antibodies, Neoplasm / immunology. Antigens, CD / immunology. Cell Adhesion Molecules / immunology. Combined Modality Therapy. Female. Humans. Immunohistochemistry. Magnetic Resonance Imaging

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12527847.001).
  • [ISSN] 0003-438X
  • [Journal-full-title] Annales d'oto-laryngologie et de chirurgie cervico faciale : bulletin de la Société d'oto-laryngologie des hôpitaux de Paris
  • [ISO-abbreviation] Ann Otolaryngol Chir Cervicofac
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Antigens, CD; 0 / CD99 protein, human; 0 / Cell Adhesion Molecules
  •  go-up   go-down


13. Chera BS, Orlando C, Villaret DB, Mendenhall WM: Follicular dendritic cell sarcoma of the head and neck: case report and literature review. Laryngoscope; 2008 Sep;118(9):1607-12
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follicular dendritic cell sarcoma of the head and neck: case report and literature review.
  • OBJECTIVES/HYPOTHESIS: This article presents a case of a patient with follicular dendritic cell sarcoma (FDS), a rare neoplasm usually of the head and neck, and reviews the literature.
  • RESULTS: Our patient presented with an FDS that had been excised from the upper neck and recurred in a level V node.
  • He was treated with neck dissection and postoperative irradiation and remains disease free 5.25 years after salvage treatment.
  • The literature search yielded 67 case reports on FDS of the head and/or neck.
  • Twenty-eight percent of patients received adjuvant radiotherapy; 18% received adjuvant chemotherapy.
  • CONCLUSIONS: We currently treat head and neck FDS with wide resection and postoperative radiotherapy.
  • [MeSH-major] Dendritic Cells, Follicular / pathology. Head and Neck Neoplasms / diagnosis. Sarcoma / diagnosis
  • [MeSH-minor] Biopsy, Fine-Needle. Diagnosis, Differential. Follow-Up Studies. Humans. Male. Middle Aged. Positron-Emission Tomography. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18596475.001).
  • [ISSN] 1531-4995
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Harb WJ, Luna MA, Patel SR, Ballo MT, Roberts DB, Sturgis EM: Survival in patients with synovial sarcoma of the head and neck: association with tumor location, size, and extension. Head Neck; 2007 Aug;29(8):731-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival in patients with synovial sarcoma of the head and neck: association with tumor location, size, and extension.
  • BACKGROUND: The medical literature on synovial sarcoma (SS) of the head and neck region is limited.
  • Thus, we determined whether clinical characteristics and treatment were associated with recurrence and survival rates in patients with SS of the head and neck.
  • METHODS: We retrospectively identified patients with a pathologic diagnosis of SS of the head and neck at our institution (a large tertiary comprehensive cancer center) and compared recurrence and survival rates by clinical characteristics and treatment.
  • RESULTS: Forty patients with SS of the head and neck were identified from 1945 to 2004 (first case in 1968), representing <5% of all head and neck sarcomas seen at our institution during this time period.
  • SS tumors were most commonly located in the neck (60%); thus, the most common symptoms were a neck mass and neck pain.
  • Patients treated with surgery and adjuvant radiotherapy had higher survival and lower recurrence rates than did those treated with surgery alone or a combination of surgery, radiotherapy, and chemotherapy.
  • CONCLUSIONS: SS of the head and neck is extremely rare, and our results should be viewed with caution given the relatively small group size and treatment over a 36-year period.
  • Treatment of SS of the head and neck should be directed toward complete surgical resection.
  • Given the known sensitivity of SS to contemporary chemotherapy, a multimodality approach should be considered in the perioperative setting, especially in high risk patients.
  • [MeSH-major] Head and Neck Neoplasms / mortality. Head and Neck Neoplasms / surgery. Neoplasm Recurrence, Local / epidemiology. Sarcoma, Synovial / mortality. Sarcoma, Synovial / surgery
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Kaplan-Meier Estimate. Linear Models. Male. Medical Records. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Texas / epidemiology. Treatment Outcome

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17274049.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Heudel P, Biston MC, Fayette J, Ramade A, Gassa F, Pommier P: Head and neck sarcoma: report of a case treated by intensity-modulated radiation therapy. Int J Clin Oncol; 2010 Jun;15(3):305-9
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Head and neck sarcoma: report of a case treated by intensity-modulated radiation therapy.
  • We report on a 71-year-old woman with parapharyngeal sarcoma.
  • After failure of four cycles of chemotherapy, intensity-modulated radiation therapy (IMRT) achieved complete clinical response and partial magnetic resonance imaging response (80%) at 24 months of follow-up.
  • The results of radiotherapy, especially IMRT, for nonresectable head and neck soft tissue sarcoma are discussed.
  • [MeSH-major] Head and Neck Neoplasms / radiotherapy. Radiotherapy, Intensity-Modulated. Sarcoma / radiotherapy
  • [MeSH-minor] Aged. Antibiotics, Antineoplastic / therapeutic use. Dose Fractionation. Doxorubicin / therapeutic use. Female. Humans. Magnetic Resonance Imaging. Pharynx. Radiotherapy Planning, Computer-Assisted. Tomography, X-Ray Computed. Treatment Failure

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1996 Mar;14(3):859-68 [8622034.001]
  • [Cites] Cancer Treat Res. 1989;44:65-74 [2577162.001]
  • [Cites] Ann Surg Oncol. 2004 Jun;11(6):619-28 [15172935.001]
  • [Cites] Semin Surg Oncol. 1994 Sep-Oct;10(5):357-63 [7997729.001]
  • [Cites] Head Neck. 2008 May;30(5):639-46 [18213722.001]
  • [Cites] J Craniomaxillofac Surg. 2009 Jan;37(1):42-8 [18804382.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):869-77 [8622035.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2006 Nov;132(11):1242-9 [17116822.001]
  • [Cites] J Clin Oncol. 2004 May 15;22(10):1902-8 [15143083.001]
  • [Cites] Am J Surg. 1989 Oct;158(4):367-72 [2802043.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Oct 15;33(3):585-93 [7558947.001]
  • [Cites] Cancer J. 2003 Jan-Feb;9(1):49-57 [12602768.001]
  • [Cites] Head Neck. 2005 Sep;27(9):814-24 [16086411.001]
  • [Cites] J Bone Joint Surg Am. 1976 Apr;58(3):317-27 [177425.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):975-84 [9169803.001]
  • [Cites] J Bone Joint Surg Am. 1980 Sep;62(6):1027-30 [7000786.001]
  • [Cites] Am J Surg. 1986 Oct;152(4):386-92 [3766868.001]
  • [Cites] Am J Clin Oncol. 2005 Jun;28(3):259-63 [15923798.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):358-64 [15380567.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Jan 1;73(1):173-7 [18501529.001]
  • [Cites] Eur J Surg Oncol. 1995 Jun;21(3):287-9 [7781799.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Feb 1;46(3):619-30 [10701741.001]
  • [Cites] Br J Cancer. 1993 Jul;68(1):201-7 [8318414.001]
  • [Cites] N Engl J Med. 2005 Aug 18;353(7):701-11 [16107623.001]
  • [Cites] Otolaryngol Head Neck Surg. 2007 Apr;136(4):549-55 [17418249.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):401-9 [16168833.001]
  • [Cites] BMC Cancer. 2007 Sep 13;7:177 [17854490.001]
  • [Cites] Semin Radiat Oncol. 1999 Oct;9(4):328-48 [10516380.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jun 1;68(2):458-64 [17363186.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Nov 1;51(3):718-28 [11597814.001]
  • [Cites] Cancer. 2003 Jan 15;97(2):485-92 [12518373.001]
  • [Cites] J Radiat Res. 2007;48 Suppl A:A1-A13 [17513896.001]
  • [Cites] J Clin Oncol. 2008 Jul 10;26(20):3440-4 [18612160.001]
  • [Cites] Hematol Oncol Clin North Am. 2001 Apr;15(2):377-88, vii [11370499.001]
  • [Cites] Eur J Cancer. 2009 Jan;45(2):228-47 [19097774.001]
  • [Cites] Lancet. 1997 Dec 6;350(9092):1647-54 [9400508.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jun 1;56(2):473-81 [12738323.001]
  • [Cites] Head Neck. 2005 Oct;27(10):916-22 [16136585.001]
  • [Cites] Cancer. 1992 Jul 1;70(1):169-77 [1606539.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):852-9 [16199316.001]
  • [Cites] Cancer. 1994 Jul 15;74(2):697-702 [8033050.001]
  • [Cites] J Bone Joint Surg Am. 1989 Mar;71(3):370-5 [2925710.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):374-87 [15380569.001]
  • [Cites] Radiat Oncol. 2006 Mar 31;1:7 [16722599.001]
  • [Cites] J Clin Oncol. 2008 Nov 10;26(32):5269-74 [18809609.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):197-203 [9440743.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Apr 1;67(5):1460-9 [17394945.001]
  • [Cites] Ann Surg. 2002 Mar;235(3):424-34 [11882765.001]
  • [Cites] Semin Oncol. 1997 Oct;24(5):526-33 [9344318.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jun 1;56(2):573-85 [12738335.001]
  • (PMID = 20195682.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 80168379AG / Doxorubicin
  •  go-up   go-down


16. Amiri-Kordestani L, Priebat D, Chia SH: Follicular dendritic cell sarcoma of the neck: case report and review of current diagnostic and management strategies. Ear Nose Throat J; 2010 Jul;89(7):E14-7
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follicular dendritic cell sarcoma of the neck: case report and review of current diagnostic and management strategies.
  • Follicular dendritic cell sarcoma (FDCS) is a rare malignant neoplasm that can clinically mimic a number of other tumors.
  • Radiation therapy and/or chemotherapy may be considered for incompletely resected tumors and for tumors with poor prognostic features, but the exact role of adjuvant therapy is unknown.
  • We report a case of cervical FDCS in a 39-year-old black man, and we review the presentation and management of this disorder, with emphasis on the differential diagnosis.
  • [MeSH-major] Dendritic Cell Sarcoma, Follicular / radiography. Dendritic Cell Sarcoma, Follicular / surgery. Head and Neck Neoplasms / radiography. Head and Neck Neoplasms / surgery
  • [MeSH-minor] Adult. Biopsy. Diagnosis, Differential. Humans. Immunohistochemistry. Male. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20628972.001).
  • [ISSN] 1942-7522
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Al-Sobhi EM, Jeha TM, Al-Taher MI: Granulocytic sarcoma causing cord compression in a pregnant woman with acute myeloid leukemia and t(8;21). Saudi Med J; 2008 Nov;29(11):1658-61
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulocytic sarcoma causing cord compression in a pregnant woman with acute myeloid leukemia and t(8;21).
  • Most frequently they occur in acute myeloid leukemia (AML), myeloproliferative disorder, and myelodysplasia.
  • It may involve any organ system, but mostly it affects the bone and soft tissue of the head and neck.
  • Granulocytic sarcoma resulting in spinal cord compression is rare.
  • In spite of the fact that t(8;21) is considered to be associated with good prognosis, patients with GS and spinal cord compression had less favorable prognosis than other AML patients with t(8;21).
  • Radiotherapy, chemotherapy, and surgical decompression are the accepted methods of therapy.
  • However, aggressive therapy such as transplantation may be warranted early in the therapeutic strategy.
  • We are reporting a pregnant female diagnosed with AML/M2 with t(8;21) at the first trimester, who relapsed with GS, and cord compression at full term.
  • She had a normal baby, and achieved second remission post-chemotherapy.
  • [MeSH-major] Chromosomes, Human, Pair 21. Chromosomes, Human, Pair 8. Leukemia, Myeloid, Acute / complications. Pregnancy Complications, Neoplastic / pathology. Sarcoma, Myeloid / pathology. Translocation, Genetic. Umbilical Cord / pathology


18. Landis DM, Aboulafia DM: Granulocytic sarcoma: an unusual complication of aleukemic myeloid leukemia causing spinal cord compression. A case report and literature review. Leuk Lymphoma; 2003 Oct;44(10):1753-60
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulocytic sarcoma: an unusual complication of aleukemic myeloid leukemia causing spinal cord compression. A case report and literature review.
  • Granulocytic sarcoma (chloroma) is a rare solid tumor resulting from the proliferation of myelogenous leukemia cells.
  • Chloromas usually present as soft tissue or bony masses of the head and neck in patients with acute myelogenous leukemia (AML) of the French-American-British M2 subtype.
  • Herein, we report the case of a man with a thoracic extradural chloroma whose presentation of progressive lumbar pain ultimately led to the diagnosis of M2 AML.
  • Surgical intervention prior to the onset of paraplegia and the prompt initiation of chemotherapy resulted in an excellent neurological and hematological outcome.
  • We also review the literature of previously reported cases of spinal cord-associated chloroma and focus on the clinical presentation and treatment of this disorder.
  • [MeSH-major] Leukemia, Myeloid, Acute / complications. Sarcoma, Myeloid / etiology. Spinal Cord Compression / etiology. Spinal Neoplasms / complications
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Magnetic Resonance Imaging. Male

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Myeloid sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14692530.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 58
  •  go-up   go-down


19. Brockstein B, Samuels B, Humerickhouse R, Arietta R, Fishkin P, Wade J, Sosman J, Vokes EE: Phase II studies of bryostatin-1 in patients with advanced sarcoma and advanced head and neck cancer. Invest New Drugs; 2001;19(3):249-54
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II studies of bryostatin-1 in patients with advanced sarcoma and advanced head and neck cancer.
  • There are few drugs that offer palliation for metastatic soft-tissue sarcoma and head and neck cancer, and drugs with new mechanisms of action warrant detailed disease specific study.
  • PATIENTS AND METHODS: Two phase II studies for patients with incurable soft tissue sarcoma (12), or head and neck cancer (12) were conducted.
  • Most patients had received prior chemotherapy.
  • RESULTS: No patients had objective responses to therapy.
  • CONCLUSIONS: Bryosytatin 1 given as a single agent for advanced adult soft tissue sarcoma and head and neck cancer is inactive.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Bone Neoplasms / drug therapy. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy. Lactones / therapeutic use. Sarcoma / drug therapy
  • [MeSH-minor] Adult. Aged. Bryostatins. Drug Administration Schedule. Female. Humans. Macrolides. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1991 Jan 5;266(1):28-33 [1845965.001]
  • [Cites] J Natl Cancer Inst. 1993 Nov 17;85(22):1812-8 [8230261.001]
  • [Cites] Br J Cancer. 1998 Nov;78(10):1337-41 [9823975.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):56-62 [9440723.001]
  • [Cites] Leukemia. 1999 Oct;13(10):1564-73 [10516758.001]
  • [Cites] Ann Oncol. 1996 Jan;7(1):15-29 [9081382.001]
  • [Cites] Clin Cancer Res. 1999 Sep;5(9):2344-8 [10499603.001]
  • [Cites] Br J Cancer. 1998;77(2):216-20 [9460991.001]
  • [Cites] Cancer Res. 1992 Jun 1;52(11):3119-24 [1591725.001]
  • [Cites] Br J Cancer. 1995 Aug;72(2):461-8 [7640233.001]
  • [Cites] Clin Cancer Res. 1998 Mar;4(3):611-8 [9533528.001]
  • [Cites] Cancer Res. 1996 Feb 15;56(4):802-8 [8631017.001]
  • [Cites] N Engl J Med. 1993 Jan 21;328(3):184-94 [8417385.001]
  • [Cites] Hematol Oncol Clin North Am. 1995 Aug;9(4):765-85 [7490240.001]
  • [Cites] Cancer Res. 1994 Jan 1;54(1):165-8 [8261437.001]
  • (PMID = 11561683.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 3P30CA14599; United States / NCI NIH HHS / CA / U01-CA63187-0451
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Bryostatins; 0 / Lactones; 0 / Macrolides; 37O2X55Y9E / bryostatin 1
  •  go-up   go-down


20. Sturgis EM, Potter BO: Sarcomas of the head and neck region. Curr Opin Oncol; 2003 May;15(3):239-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sarcomas of the head and neck region.
  • PURPOSE OF REVIEW: This review discusses the classification, etiology, diagnosis, evaluation, treatment, and prognosis of sarcoma of the head and neck region.
  • RECENT FINDINGS: Sarcomas account for less than 1% of all malignancies in the United States with only 5 to 15% of these sarcomas occurring in the head and neck region.
  • However, about 1 in 3 pediatric sarcomas will occur in the head and neck region.
  • Pathologic classification is critical to the ultimate treatment and prognosis of sarcoma of the head and neck.
  • Osteosarcoma, rhabdomyosarcoma, malignant fibrous histiocytoma, and angiosarcoma are the most common types of sarcoma to occur in the head and neck region; however, up to 20% of head and neck sarcomas will remain unclassified.
  • Adjuvant chemotherapy is being utilized and/or studied for most high-grade sarcomas and adjuvant radiotherapy is important for disease control in high-grade soft-tissue sarcomas.
  • SUMMARY: Sarcomas of the head and neck region are rare malignancies often without a clear etiology.
  • [MeSH-major] Head and Neck Neoplasms / pathology. Head and Neck Neoplasms / therapy. Sarcoma / pathology. Sarcoma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Chemotherapy, Adjuvant. Child. Child, Preschool. Combined Modality Therapy. Female. Hemangiosarcoma / mortality. Hemangiosarcoma / pathology. Hemangiosarcoma / therapy. Humans. Male. Middle Aged. Neoplasm Staging. Osteosarcoma / mortality. Osteosarcoma / pathology. Osteosarcoma / therapy. Prognosis. Radiotherapy, Adjuvant. Rhabdomyosarcoma / mortality. Rhabdomyosarcoma / pathology. Rhabdomyosarcoma / therapy. Risk Assessment. Surgical Procedures, Operative / methods. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12778019.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 157
  •  go-up   go-down


21. Whaley JT, Indelicato DJ, Morris CG, Hinerman RW, Amdur RJ, Mendenhall WM, Keole SR, Marcus RB Jr: Ewing tumors of the head and neck. Am J Clin Oncol; 2010 Aug;33(4):321-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ewing tumors of the head and neck.
  • PURPOSE: Retrospective review describing the 40-year University of Florida experience treating Ewing tumors of the head-and-neck region with a summary of the pertinent literature.
  • PATIENTS AND METHODS: Nine patients were diagnosed and treated for Ewing sarcoma of the head and neck at our institution between 1965 and 2007.
  • Primary sites included: mandible (3 patients), calvarium (2 patients), paranasal sinus (2 patients), oral cavity (1 patient), and the extraosseous soft tissue of the neck (1 patient).
  • The median age at diagnosis was 13.0 years (range, 6.3-20.1 years).
  • RESULTS: All patients received multiagent chemotherapy and radiation therapy to a median dose of 55.8 Gy (range, 36-67.2 Gy).
  • A literature search revealed 8 previous series with Ewing tumors of the head and neck analyzed as subsets of larger studies.
  • CONCLUSIONS: In the context of limited data on head and neck Ewing tumors, combined modality therapy provides excellent local control with reasonable acute and late toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy. Sarcoma, Ewing / drug therapy. Sarcoma, Ewing / radiotherapy
  • [MeSH-minor] Combined Modality Therapy. Follow-Up Studies. Humans. Radiotherapy Dosage. Retrospective Studies. Survival Analysis. Survival Rate. Time Factors

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19841575.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 40
  •  go-up   go-down


22. Ludwig A: [Extranodal follicular dendritic cell sarcoma of the tonsils]. HNO; 2006 Sep;54(9):701-4
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Extranodal follicular dendritic cell sarcoma of the tonsils].
  • Follicular dendritic cell (FDC) sarcoma is a rare tumor deriving from dendritic cells of the lymphoid follicle.
  • Only a few cases of extranodal manifestation of FDC sarcoma of the head and neck have been reported.
  • We describe the case of a 47-year-old woman with a FDC sarcoma of the left tonsil that first manifested 11 years ago.
  • She has suffered three recurrences since this time, at continually reducing intervals.
  • Histologically, the neoplasm consisted of an increased number of spindle-shaped cells with partly hyperchromatic nuclei.
  • The patient underwent local tumor excisions, and then received an adjuvant chemotherapy with doxorubicin and ifosfamide when she presented with the third recurrence.
  • The 11 year follow-up bears out a more aggressive behaviour of FDC sarcoma than first assumed.
  • Therefore, a wide local excision, eventually combined with neck dissection in the case of recurrences, seems to be necessary.
  • [MeSH-major] Dendritic Cells, Follicular / pathology. Sarcoma / pathology. Tonsillar Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 2002 May-Jun;64(3):229-32 [12037393.001]
  • [Cites] Am J Hematol. 1998 Oct;59(2):161-7 [9766802.001]
  • [Cites] Ear Nose Throat J. 2003 Jul;82(7):507-9 [12955835.001]
  • [Cites] Oral Oncol. 2003 Jun;39(4):415-9 [12676264.001]
  • [Cites] Mod Pathol. 2002 Jan;15(1):50-8 [11796841.001]
  • [Cites] Am J Pathol. 1986 Mar;122(3):562-72 [2420185.001]
  • [Cites] Am J Surg Pathol. 1996 Aug;20(8):944-55 [8712294.001]
  • [Cites] Am J Otolaryngol. 2002 Mar-Apr;23(2):93-8 [11893977.001]
  • [Cites] Head Neck. 1999 May;21(3):273-5 [10208672.001]
  • [Cites] J Neurosurg. 2003 Dec;99(6):1089-90 [14705740.001]
  • [Cites] Am J Surg Pathol. 1994 Feb;18(2):148-57 [8291653.001]
  • [Cites] Cancer. 1997 Jan 15;79(2):294-313 [9010103.001]
  • (PMID = 16389561.001).
  • [ISSN] 0017-6192
  • [Journal-full-title] HNO
  • [ISO-abbreviation] HNO
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


23. Rapidis AD: Sarcomas of the head and neck in adult patients: current concepts and future perspectives. Expert Rev Anticancer Ther; 2008 Aug;8(8):1271-97
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sarcomas of the head and neck in adult patients: current concepts and future perspectives.
  • Sarcomas comprise a heterogeneous and biologically diverse group of malignant neoplasms having as a common denominator their origin from mesenchymal cells.
  • Head and neck sarcomas account for 4 to less than 20% of total body sarcomas depending on the criteria, such as age of patients (pediatric vs adult population), type of sarcomas (soft-tissue vs bony sarcomas) and site of location.
  • Although head and neck sarcomas occur infrequently in adults, in the pediatric population one in three sarcomas will occur in the head and neck region.
  • Most head and neck sarcomas are of the soft-tissue type, with only 20% being of bony or cartilaginous origin.
  • Osteosarcomas, rhabdomyosarcomas, pleomorphic sarcomas (malignant fibrous histiocytomas), fibrosarcomas and angiosarcomas are among the most common histologic types of sarcoma found in the head and neck.
  • Surgery has been the primary therapeutic approach for the management of head and neck sarcomas.
  • Survival rates for head and neck sarcomas suggest worse outcomes than for their extremity counterparts.
  • Lymph node metastasis only occurs in 3-10% of sarcomas of the head and neck.
  • Conflicting results have been reported on the benefit from the use of chemotherapy as an adjuvant or neoadjuvant regimen, especially for high-grade sarcomas in long-term survival or local disease control.
  • Encouraging results have recently been reported with the use of molecular targeted therapies with tyrosine kinase inhibitors and antiangiogenetic agents.
  • [MeSH-major] Head and Neck Neoplasms / therapy. Sarcoma / therapy

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18699765.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


24. Kartha SS, Bumpous JM: Synovial cell sarcoma: diagnosis, treatment, and outcomes. Laryngoscope; 2002 Nov;112(11):1979-82
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synovial cell sarcoma: diagnosis, treatment, and outcomes.
  • OBJECTIVES/HYPOTHESIS: Synovial cell sarcoma is a mesenchymal tumor predominantly of the lower extremities.
  • Three percent of cases arise in the head and neck region.
  • It is thought that head and neck synovial sarcoma has a better prognosis than tumors of the extremities.
  • Our experience has demonstrated aggressive behavior of this neoplasm in the head and neck.
  • METHODS: We obtained the records of patients diagnosed with head and neck synovial sarcoma from the Tumor Registry of the University of Louisville School of Medicine (Louisville, KY) and affiliated hospitals for data compiled between January 1990 and December 2000.
  • Data on patient demographics, clinical findings and symptoms, histological findings, treatment, extent of disease, recurrence, and survival were recorded.
  • The literature was reviewed identifying reports of synovial cell sarcoma.
  • RESULTS: Five consecutive patients with synovial cell sarcoma were assessed at our facility.
  • All patients received chemotherapy after recurrence.
  • Four of the five patients had local recurrence, and all five of the patients developed distant metastases.
  • CONCLUSIONS: Synovial cell sarcoma of the head and neck is a disease of young people and carries a poor prognosis.
  • The aggressive nature of the disease may require modification of accepted treatment modalities and sequence.
  • [MeSH-major] Head and Neck Neoplasms / diagnosis. Head and Neck Neoplasms / therapy. Sarcoma, Synovial / diagnosis. Sarcoma, Synovial / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Humans. Male. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12439166.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Kawakami K: Cancer gene therapy utilizing interleukin-13 receptor alpha2 chain. Curr Gene Ther; 2005 Apr;5(2):213-23
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer gene therapy utilizing interleukin-13 receptor alpha2 chain.
  • Among them, interleukin-13 receptor (IL-13R) alpha2 chain is expressed on certain types of cancer cells including glioblastoma, AIDS Kaposi's sarcoma, and head and neck cancer.
  • In order to achieve a broad therapeutic window for IL13-PE, plasmid-mediated gene transfer of IL-13Ralpha2 in cancer cells was employed in vitro and in vivo.
  • In addition, safety issues and possible future directions utilizing this therapeutic approach are discussed.
  • [MeSH-major] Genetic Therapy. Neoplasms / therapy. Receptors, Interleukin / genetics


26. Blackwell KL, Kirkpatrick JP, Snyder SA, Broadwater G, Farrell F, Jolliffe L, Brizel DM, Dewhirst MW: Human recombinant erythropoietin significantly improves tumor oxygenation independent of its effects on hemoglobin. Cancer Res; 2003 Oct 1;63(19):6162-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor oxygenation is known to be an important predictive/prognostic marker in a variety of tumors, including cervix, head/neck, sarcoma, non-small cell of the lung, and breast.
  • This study randomized 30 nonanemic, female Fischer 344 rats into three treatment arms to examine the effects of recombinant human erythropoietin (EPO) on R3230 rodent mammary carcinoma oxygenation.
  • The three treatment arms were: (a) placebo;.
  • On day 22, median tumor volume was 399 mm(3) (range: 65-950 mm(3)), and no differences in tumor volume were seen between treatment arms.
  • Mean hematocrit was equal between arms at therapy initiation but were significantly higher for both arms receiving EPO at day 22 (placebo versus Arm B versus Arm C; Wilcoxon P = 0.052).
  • [MeSH-major] Adenocarcinoma / blood. Adenocarcinoma / drug therapy. Erythropoietin / pharmacology. Hemoglobins / metabolism. Mammary Neoplasms, Experimental / blood. Mammary Neoplasms, Experimental / drug therapy. Oxygen / blood
  • [MeSH-minor] Animals. Female. Humans. Neoplasm Transplantation. Partial Pressure. Random Allocation. Rats. Rats, Inbred F344. Recombinant Proteins

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. OXYGEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14559797.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 40355
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hemoglobins; 0 / Recombinant Proteins; 11096-26-7 / Erythropoietin; S88TT14065 / Oxygen
  •  go-up   go-down


27. Strome SE, Kawakami K, Alejandro D, Voss S, Kasperbauer JL, Salomao D, Chen L, Maki RA, Puri RK: Interleukin 4 receptor-directed cytotoxin therapy for human head and neck squamous cell carcinoma in animal models. Clin Cancer Res; 2002 Jan;8(1):281-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interleukin 4 receptor-directed cytotoxin therapy for human head and neck squamous cell carcinoma in animal models.
  • Receptors for interleukin 4 (IL-4R) are overexpressed on the surface of various human solid tumors including renal cell carcinoma, glioblastoma, Kaposi's sarcoma, and head and neck squamous cell carcinoma (SCCHN).
  • On the basis of this preferential receptor overexpression, a novel IL-4R-targeted cytotoxin, IL-4 (38-37)-PE38KDEL, was developed in which circularly permuted IL-4 [IL-4 (38-37)] was fused to mutated form of Pseudomonas exotoxin (PE38KDEL).
  • Despite the recognized expression of the IL-4R on SSCHN, the utility of a receptor-specific fusion protein for the treatment of this disease remains unknown.
  • The purpose of this study was to establish the utility of IL-4 (38-37)-PE38KDEL for the treatment of established SSCHN in animal models of human disease.
  • Expression of IL-4R in SCCHN was confirmed by immunohistochemistry with eight of eight tissue sections expressing IL-4R.
  • Subcultured tumor cells after intratumoral treatment with IL-4 toxin did not develop resistance to the drug.
  • These data demonstrate that IL-4 (38-37)-PE38KDEL is effective in mediating significant antitumor effects in SCCHN and may represent an attractive therapeutic option for patients with advanced cancers of the upper aerodigestive tract.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Cell Division / physiology. Cytotoxins / therapeutic use. Head and Neck Neoplasms / therapy. Immunotoxins / therapeutic use. Receptors, Interleukin-4 / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Animals. Female. Humans. Immunoenzyme Techniques. Injections, Intralesional. Interleukin-4. Male. Mice. Mice, Nude. Middle Aged. Recombinant Proteins / therapeutic use. Transplantation, Heterologous. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11801570.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NIDCR NIH HHS / DE / K23 DE 00459-2
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytotoxins; 0 / Immunotoxins; 0 / Receptors, Interleukin-4; 0 / Recombinant Proteins; 0 / interleukin 4 (38-37)-PE38KDEL; 207137-56-2 / Interleukin-4
  •  go-up   go-down


28. Santhanam S, Decatris M, O'Byrne K: Potential of interferon-alpha in solid tumours: part 2. BioDrugs; 2002;16(5):349-72
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The second part of this review examines the use of recombinant interferon-alpha (rIFNalpha) in the following solid tumours: superficial bladder cancer, Kaposi's sarcoma, head and neck cancer, gastrointestinal cancers, lung cancer, mesothelioma and ovarian, breast and cervical malignancies.
  • In superficial bladder cancer, intravesical rIFNalpha has a promising role as second-line therapy in patients resistant or intolerant to intravesical bacille Calmette-Guérin (BCG).
  • In HIV-associated Kaposi's sarcoma, rIFNalpha is active as monotherapy and in combination with antiretroviral agents, especially in patients with CD4 counts >200/mm(3), no prior opportunistic infections and nonvisceral disease. rIFNalpha has shown encouraging results when used in combination with retinoids in the chemoprevention of head and neck squamous cell cancers.
  • In neuroendocrine tumours, including carcinoid tumour, low-dosage (</=3 MU) or intermediate-dosage (5 to 10 MU) rIFNalpha is indicated as second-line treatment, either with octreotide or alone in patients resistant to somatostatin analogues.
  • Intracavitary IFNalpha may be useful in malignant pleural effusions from mesothelioma.
  • Similarly, intraperitoneal IFNalpha may have a role in the treatment of minimal residual disease in ovarian cancer.
  • IFNalpha may have a role as a radiosensitising agent for the treatment of cervical cancer; however, this requires confirmation in randomised trials.
  • On the basis of current evidence, the routine use of rIFNalpha is not recommended in the therapy of head and neck squamous cell cancers, upper gastrointestinal tract, colorectal and lung cancers, or mesothelioma.
  • Studies of IFNalpha-stimulated gene expression, which are now feasible, should help to identify molecular predictors of response and allow us to target therapy more selectively to patients with solid tumours responsive to IFNalpha.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Interferon-alpha / therapeutic use. Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12408739.001).
  • [ISSN] 1173-8804
  • [Journal-full-title] BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
  • [ISO-abbreviation] BioDrugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha
  • [Number-of-references] 391
  •  go-up   go-down


29. Zuccari G, Bergamante V, Carosio R, Gotti R, Montaldo PG, Orienti I: Micellar complexes of all-trans retinoic acid with polyvinylalcohol-nicotinoyl esters as new parenteral formulations in neuroblastoma. Drug Deliv; 2009 May;16(4):189-95
Hazardous Substances Data Bank. POLYVINYL ALCOHOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All-trans-retinoic acid (ATRA) is now included in many antitumor therapeutic schemes for the treatment of acute promyelocytic leukemia, Kaposi's sarcoma, head and neck squamous cell carcinoma, ovarian carcinoma, bladder cancer, and neuroblastoma.
  • Unfortunately, its poor aqueous solubility hampers its parenteral formulation, whereas oral administration of ATRA is associated with progressively diminishing drug levels in plasma, which is related to induction of retinoic acid-binding proteins and increased drug catabolism by cytochrome P450-mediated reactions.
  • An ATRA formulation, obtained by complexation of the drug into polymeric micelles, might be suitable for parenteral administration overcoming these unwanted effects.
  • The physicochemical characteristics of the polymers and the complexes were analyzed by 1H-NMR, Dynamic Light Scattering (DLS), Capillary Electophoresis (CE), and were correlated with the complex ability to improve the drug solubilization and release the free drug in an aqueous environment.
  • The PVA substitution degree calculated from 1H-NMR was found to be 5.0%, 8.2%, 15.3% (nicotinoyl moiety:PVA monomer molar ratio), while capillary electrophoresis analysis on the complexes revealed that the drug loadings were 0.95%, 1.20%, 4.76% (ATRA:polymer w:w) for PVA substitution degrees of 5.0%, 8.2%, and 15.3%, respectively.
  • Drug fractional release did not exceed 8% after 48 h.
  • These data suggest that the systems analyzed may be suitable carriers for parenteral administration of ATRA and other hydrophobic antitumor drugs, where the carriers are required to improve drug aqueous solubility and delay drug release almost after their accumulation in solid tumors.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Cell Proliferation / drug effects. Infusions, Parenteral. Neuroblastoma / therapy. Tretinoin / administration & dosage
  • [MeSH-minor] Chemistry, Pharmaceutical. Drug Administration Routes. Drug Carriers / administration & dosage. Drug Carriers / chemistry. Esters / chemistry. Humans. Micelles. Polyvinyl Alcohol / chemistry. Solubility. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19241235.001).
  • [ISSN] 1521-0464
  • [Journal-full-title] Drug delivery
  • [ISO-abbreviation] Drug Deliv
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drug Carriers; 0 / Esters; 0 / Micelles; 5688UTC01R / Tretinoin; 9002-89-5 / Polyvinyl Alcohol
  •  go-up   go-down






Advertisement